Clinical Trials on Melanom%2C+experimentell

Total 3197 results

Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Piramal Enterprises Limited
Melanoma Research Foundation Breakthrough Consortium

Suspended

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

United States
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Mayo Clinic

Active, not recruiting

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant Melanoma

United States
University of Wisconsin, Madison

Recruiting

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Melanoma | Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Power Life Sciences Inc.

Not yet recruiting

Investigating Participation Patterns Among Stage IV Melanoma Patients

Stage IV Melanoma

United States
Fudan University

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Washington University School of Medicine
Genentech, Inc.

Terminated

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Stage II Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)

Melanoma Stage III

Australia
Institut Curie

Completed

Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma

Choroidal Melanoma, Diffuse

France
Novo Nordisk A/S

Completed

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Cancer | Malignant Melanoma

Australia
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
Mayo Clinic
Merck Sharp & Dohme LLC

Terminated

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

Stage IV Melanoma

United States
M.D. Anderson Cancer Center
Genta Incorporated

Completed

Phase II Study of Tesetaxel in Metastatic Melanoma

Cancer | Advanced Melanoma

United States
Hoffmann-La Roche

Withdrawn

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms
Italian Network for Tumor Biotherapy
Bristol-Myers Squibb

Completed

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1)

Metastatic Malignant Melanoma

Italy
NYU Langone Health

Completed

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

Metastatic Malignant Melanoma
Krankenhaus Nordwest

Terminated

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Chemo-refractory Melanoma

Germany
National Cancer Institute (NCI)

Completed

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

High-Risk Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
AI Labs Group S.L
Hospital de Basurto; Osakidetza; Hospital de Cruces; Servicio Vasco de Salud Osakidetza...

Recruiting

Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma (LEGIT_MC_EVCDA)

Melanoma | Melanoma, Skin

Spain
Centre Hospitalier Universitaire de Nice

Recruiting

Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma (MEL-META)

Melanoma (Skin)

France
MelanomaPRO, Russia

Recruiting

Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice (FORA)

Advanced Melanoma

Russian Federation
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Advanced Melanoma

China
California Pacific Medical Center Research Institute
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Metastatic Melanoma

United States
Fudan University
Zhejiang Cancer Hospital; Fujian Cancer Hospital; The Affiliated Nanjing Drum...

Recruiting

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma (MTAM)

Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Mucosal Melanoma

China
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Advanced Melanoma
California Pacific Medical Center Research Institute
Tesaro, Inc.; Vanderbilt-Ingram Cancer Center; Huntsman Cancer Institute

Recruiting

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Metastatic Melanoma

United States
Markus Joerger

Recruiting

Tinostamustine and Nivolumab in Advanced Melanoma (ENIgMA)

Malignant Melanoma

Switzerland
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
East and North Hertfordshire NHS Trust
King's College London

Recruiting

Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics (PRIMM)

Melanoma (Skin)

United Kingdom
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
Chung Mei Biopharma Co., Ltd

Not yet recruiting

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

Advanced Melanoma
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI)

Recruiting

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary (MelBase)

Malignant Melanoma

France
Medical University of Vienna

Recruiting

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

Uveal Melanoma

Austria
Reata, a wholly owned subsidiary of Biogen

Withdrawn

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Malignant Melanoma
University of Sydney
Melanoma and Skin Cancer Trials Limited

Completed

Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. (MEL-SELF)

Melanoma (Skin)

Australia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Melanoma | Malignant Melanoma
Hospital das Clínicas de Ribeirão Preto
Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas...

Enrolling by invitation

Melphalan Chemoreduction for Ocular Melanoma (MELCOM)

Uveal Melanoma

Brazil
Hoffmann-La Roche

Completed

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Malignant Melanoma

Switzerland
Abramson Cancer Center at Penn Medicine
Novartis Pharmaceuticals

Terminated

Study of Temzolomide and Gleevec in Advanced Melanoma

Melanoma | Advanced Melanoma

United States

Clinical Trials on Melanom%2C+experimentell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations